Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOES Pilot Study
NCT07000734Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib, quercetin and vortioxetine in aging and No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity, sponsored by Washington University School of Medicine. Primary endpoint: Number of participants who completed the outcome measure assessments and intervention at 5 months. Started Jul 2025; status: completed.
02
Drugs
dasatinibquercetinvortioxetine
03
Conditions
agingNo canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT07000734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000734.